ImStem won $1.1 million stem cell research grant from State of Connecticut
ImStem Biotechnology’s Drs. Xiaofang Wang and Ren-He Xu were awarded $1.1 million in state stem cell funding.
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
ImStem Biotechnology’s Drs. Xiaofang Wang and Ren-He Xu were awarded $1.1 million in state stem cell funding.
“ImStem's work is not only important from a public health standpoint, but is part of a wider growing biotech industry that is creating well-paying, high-tech jobs,” said Mike Demicco (D-Farmington).